{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:39:13Z","timestamp":1790285953716,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer-associated thrombosis (CAT) encompasses manifestations of deep venous thrombosis and\/or pulmonary embolism occurring during the evolution of cancer. CAT represents one of the major cardiovascular complications associated with cancer and anti-cancer treatments, and the second leading cause of death after cancer progression. The rate of venous thromboembolism (VTE) recurrence is augmented in patients with cancer, together with the risk of bleeding, when compared with subjects without malignancy. Thus, decisions on optimal anticoagulation strategy should carefully balance both thrombotic and bleeding risk. While low-molecular weight heparins and direct oral anticoagulants now represent the standard-of-care in patients with cancer, newer pharmacologic compounds able to prevent VTE recurrence while minimizing the hemorrhagic risk are needed, and currently under investigation. In particular, factor XI inhibitors have emerged as potentially safe drugs in this highly vulnerable population, although results from dedicated clinical trials are waited to confirm this hypothesis. This review aims to summarize current management, controversies, and latest developments in pharmacotherapeutic approaches for patients with CAT.<\/jats:p>","DOI":"10.1007\/s11239-025-03154-7","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T16:13:05Z","timestamp":1753805585000},"page":"1095-1108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of cancer-associated venous thromboembolism: Perspectives on optimizing current therapeutics with a focus on factor XI inhibition"],"prefix":"10.1007","volume":"58","author":[{"given":"Massimiliano","family":"Camilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Potere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Laudani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Freixa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Burzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lopez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"3154_CR1","doi-asserted-by":"publisher","unstructured":"Falanga A, Schieppati F, Russo L (2019) Pathophysiology 1. Mechanisms of thrombosis in cancer patients. Cancer Treat Res 179:11\u201336. https:\/\/doi.org\/10.1007\/978-3-030-20315-3_2. PMID: 31317478","DOI":"10.1007\/978-3-030-20315-3_2"},{"key":"3154_CR2","doi-asserted-by":"publisher","unstructured":"Becattini C, Cimini LA (2023) Provoked vs minimally provoked vs unprovoked VTE: does it matter? hematology am Soc hematol Educ program. 2023(1):600\u2013605. https:\/\/doi.org\/10.1182\/hematology.2023000492. PMID: 38066936; PMCID: PMC10727063","DOI":"10.1182\/hematology.2023000492"},{"key":"3154_CR3","doi-asserted-by":"publisher","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632-4. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x. PMID: 17319909","DOI":"10.1111\/j.1538-7836.2007.02374.x"},{"key":"3154_CR4","doi-asserted-by":"publisher","first-page":"100739","DOI":"10.1016\/j.lanepe.2023.100739","volume":"34","author":"HT S\u00f8rensen","year":"2023","unstructured":"S\u00f8rensen HT, Pedersen L, van Es N, B\u00fcller HR, Horv\u00e1th-Puh\u00f3 E (2023) Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study. Lancet Reg Health Eur 34:100739. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100739PMID: 37809052; PMCID: PMC10558815","journal-title":"Lancet Reg Health Eur"},{"key":"3154_CR5","doi-asserted-by":"publisher","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959\u20131969. https:\/\/doi.org\/10.1182\/blood.2020007338. PMID: 33171494","DOI":"10.1182\/blood.2020007338"},{"issue":"6","key":"3154_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","volume":"43","author":"L Girardi","year":"2023","unstructured":"Girardi L, Wang TF, Ageno W, Carrier M (2023) Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism. Arterioscler Thromb Vasc Biol 43(6):824\u2013831. https:\/\/doi.org\/10.1161\/ATVBAHA.123.318779Epub 2023 May 4. PMID: 37139840","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3154_CR7","doi-asserted-by":"publisher","first-page":"114263","DOI":"10.1016\/j.ejca.2024.114263","volume":"209","author":"E Van Cutsem","year":"2024","unstructured":"Van Cutsem E, Mah\u00e9 I, Felip E et al (2024) Treating cancer-associated venous thromboembolism: a practical approach. Eur J Cancer 209:114263. https:\/\/doi.org\/10.1016\/j.ejca.2024.114263Epub 2024 Aug 5. PMID: 39128187","journal-title":"Eur J Cancer"},{"key":"3154_CR8","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, ESC Scientific Document Group (2022). ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244. Erratum in: Eur Heart J. 2023;44(18):1621. https:\/\/doi.org\/10.1093\/eurheartj\/ehad196. PMID: 36017568","DOI":"10.1093\/eurheartj\/ehac244"},{"issue":"3","key":"3154_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","volume":"130","author":"I Mah\u00e9","year":"2017","unstructured":"Mah\u00e9 I, Chidiac J, Bertoletti L et al (2017) RIETE investigators. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med 130(3):337\u2013347. https:\/\/doi.org\/10.1016\/j.amjmed.2016.10.017Epub 2016 Nov 22. PMID: 27884650","journal-title":"Am J Med"},{"issue":"11","key":"3154_CR10","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1055\/s-0044-1788997","volume":"124","author":"D Pastori","year":"2024","unstructured":"Pastori D, Palareti G (2024) Open issues in the choice and management of direct oral anticoagulants in patients with cancer-related venous thromboembolism. Thromb Haemost 124(11):1024\u20131026. https:\/\/doi.org\/10.1055\/s-0044-1788997Epub 2024 Aug 6. PMID: 39106896","journal-title":"Thromb Haemost"},{"issue":"5","key":"3154_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, ESMO Guidelines Committee et al (2023) Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol 34(5):452\u2013467. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014Epub 2023 Jan 10. PMID: 36638869","journal-title":"Ann Oncol"},{"issue":"11","key":"3154_CR12","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1111\/jth.15011","volume":"18","author":"H Skille","year":"2020","unstructured":"Skille H, Paulsen B, Hveem K et al (2020) Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event. J Thromb Haemost 18(11):2861\u20132869. https:\/\/doi.org\/10.1111\/jth.15011Epub 2020 Oct 5. PMID: 32671915","journal-title":"J Thromb Haemost"},{"key":"3154_CR13","doi-asserted-by":"publisher","unstructured":"Mantha S, Rak J (2022) Cancer genetic alterations and risk of venous thromboembolism. Thromb Res 213 Suppl 1:S29-S34. https:\/\/doi.org\/10.1016\/j.thromres.2021.12.008. Epub 2022 May 26. PMID: 36210557","DOI":"10.1016\/j.thromres.2021.12.008"},{"key":"3154_CR14","doi-asserted-by":"publisher","unstructured":"Meyer G, Planquette B (2020) Incidental venous thromboembolism, detected by chance, but still venous thromboembolism. Eur Respir J 55(2):2000028. https:\/\/doi.org\/10.1183\/13993003.00028-2020. PMID: 32029648","DOI":"10.1183\/13993003.00028-2020"},{"issue":"13","key":"3154_CR15","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","volume":"139","author":"U Campia","year":"2019","unstructured":"Campia U, Moslehi JJ, Amiri-Kordestani L et al (2019) Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation 139(13):e579\u2013e602. https:\/\/doi.org\/10.1161\/CIR.0000000000000641","journal-title":"Circulation"},{"issue":"17","key":"3154_CR16","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1200\/JCO.2010.34.0984","volume":"29","author":"PL den Exter","year":"2011","unstructured":"den Exter PL, Hooijer J, Dekkers OM, Huisman MV (2011) Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 29(17):2405\u20132409 Epub 2011 May 9. PMID: 21555690","journal-title":"J Clin Oncol"},{"issue":"20","key":"3154_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1200\/JCO.18.01977","volume":"37","author":"N Kraaijpoel","year":"2019","unstructured":"Kraaijpoel N, Bleker SM, Meyer G et al (2019) UPE investigators. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study. J Clin Oncol 37(20):1713\u20131720 Epub 2019 May 22. PMID: 31116676","journal-title":"J Clin Oncol"},{"issue":"4","key":"3154_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C et al (2021) American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442","journal-title":"Blood Adv"},{"issue":"5","key":"3154_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520. https:\/\/doi.org\/10.1200\/JCO.19.01461Epub 2019 Aug 5. PMID: 31381464","journal-title":"J Clin Oncol"},{"key":"3154_CR20","doi-asserted-by":"publisher","unstructured":"Farge D, Frere C, Connors JM et al (2019) International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566-e581. https:\/\/doi.org\/10.1016\/S1470-2045(19)30336-5. Epub 2019 Sep 3. PMID: 31492632","DOI":"10.1016\/S1470-2045(19)30336-5"},{"key":"3154_CR21","doi-asserted-by":"publisher","unstructured":"Lee AY, Levine MN, Baker RI et al (2003) Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u201353. https:\/\/doi.org\/10.1056\/NEJMoa025313. PMID: 12853587","DOI":"10.1056\/NEJMoa025313"},{"issue":"7","key":"3154_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P et al (2018) Hokusai VTE Cancer investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948Epub 2017 Dec 12. PMID: 29231094","journal-title":"N Engl J Med"},{"key":"3154_CR23","doi-asserted-by":"publisher","unstructured":"Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034. Epub 2018 May 10. PMID: 29746227","DOI":"10.1200\/JCO.2018.78.8034"},{"issue":"2","key":"3154_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421. https:\/\/doi.org\/10.1111\/jth.14662Epub 2019 Nov 28. PMID: 31630479","journal-title":"J Thromb Haemost"},{"issue":"17","key":"3154_CR25","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G et al (2020) Caravaggio investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1915103Epub 2020 Mar 29. PMID: 32223112","journal-title":"N Engl J Med"},{"key":"3154_CR26","doi-asserted-by":"publisher","first-page":"103074","DOI":"10.1016\/j.critrevonc.2020.103074","volume":"154","author":"M Camilli","year":"2020","unstructured":"Camilli M, Lombardi M, Vescovo GM et al (2020) Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: a systematic review and meta-analysis. Crit Rev Oncol Hematol 154:103074. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103074Epub 2020 Aug 2. PMID: 32911455","journal-title":"Crit Rev Oncol Hematol"},{"key":"3154_CR27","doi-asserted-by":"publisher","unstructured":"Mulder FI, Bosch FTM, Young AM et al (2020) Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 136(12):1433\u20131441. https:\/\/doi.org\/10.1182\/blood.2020005819. PMID: 32396939","DOI":"10.1182\/blood.2020005819"},{"issue":"7","key":"3154_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1055\/s-0040-1712098","volume":"120","author":"M Giustozzi","year":"2020","unstructured":"Giustozzi M, Agnelli G, Del Toro-Cervera J et al (2020) Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and Meta-Analysis. Thromb Haemost 120(7):1128\u20131136. https:\/\/doi.org\/10.1055\/s-0040-1712098Epub 2020 May 4. PMID: 32365386","journal-title":"Thromb Haemost"},{"key":"3154_CR29","doi-asserted-by":"publisher","first-page":"103925","DOI":"10.1016\/j.amsu.2022.103925","volume":"79","author":"N Yamani","year":"2022","unstructured":"Yamani N, Unzek S, Almas T et al (2022) DOACs or VKAs or LMWH - what is the optimal regimen for cancer-associated venous thromboembolism? A systematic review and meta-analysis. Ann Med Surg (Lond) 79:103925. https:\/\/doi.org\/10.1016\/j.amsu.2022.103925PMID: 35860059; PMCID: PMC9289311","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"3154_CR30","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","volume":"22","author":"RD McBane","year":"2024","unstructured":"McBane RD 2nd, Loprinzi CL, Zemla T et al (2024) EVE trial investigators. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. J Thromb Haemost 22(6):1704\u20131714 Epub 2024 Mar 25","journal-title":"J Thromb Haemost"},{"key":"3154_CR31","doi-asserted-by":"publisher","unstructured":"Yamashita Y, Morimoto T, Muraoka N et al (2024) ONCO PE Trial Investigators. Rivaroxaban for 18 months versus 6 months in patients with cancer and acute low-risk pulmonary embolism: an open-label, multicenter, randomized clinical trial (ONCO PE Trial). Circulation. Nov 18. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072758. PMID: 39556015","DOI":"10.1161\/CIRCULATIONAHA.124.072758"},{"issue":"14","key":"3154_CR32","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","volume":"392","author":"I Mah\u00e9","year":"2025","unstructured":"Mah\u00e9 I, Carrier M, Mayeur D et al (2025) API-CAT investigators. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med 392(14):1363\u20131373. https:\/\/doi.org\/10.1056\/NEJMoa2416112Epub 2025 Mar 29. PMID: 40162636","journal-title":"N Engl J Med"},{"key":"3154_CR33","doi-asserted-by":"publisher","unstructured":"Khorana AA, Mackman N, Falanga A et al (2022) Cancer-associated venous thromboembolism. Nat Rev Dis Primers 8(1):11. https:\/\/doi.org\/10.1038\/s41572-022-00336-y. PMID: 35177631","DOI":"10.1038\/s41572-022-00336-y"},{"issue":"10","key":"3154_CR34","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484\u20133488. https:\/\/doi.org\/10.1182\/blood-2002-01-0108Epub 2002 Jul 12. PMID: 12393647","journal-title":"Blood"},{"issue":"1","key":"3154_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1160\/TH15-08-0686","volume":"117","author":"AT Cohen","year":"2017","unstructured":"Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C (2017) Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 117(1):57\u201365. https:\/\/doi.org\/10.1160\/TH15-08-0686Epub 2016 Oct 6. PMID: 27709226","journal-title":"Thromb Haemost"},{"key":"3154_CR36","doi-asserted-by":"publisher","first-page":"l4363","DOI":"10.1136\/bmj.l4363","volume":"366","author":"F Khan","year":"2019","unstructured":"Khan F, Rahman A, Carrier M et al (2019) MARVELOUS collaborators. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 366:l4363. https:\/\/doi.org\/10.1136\/bmj.l4363PMID: 31340984; PMCID: PMC6651066","journal-title":"BMJ"},{"issue":"10","key":"3154_CR37","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.7326\/M21-1094","volume":"174","author":"F Khan","year":"2021","unstructured":"Khan F, Tritschler T, Kimpton M et al (2021) MAJESTIC collaborators. Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis. Ann Intern Med 174(10):1420\u20131429 Epub 2021 Sep 14. PMID: 34516270","journal-title":"Ann Intern Med"},{"issue":"3","key":"3154_CR38","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1055\/s-0041-1736037","volume":"5","author":"A Falanga","year":"2021","unstructured":"Falanga A, Gal GL, Carrier M et al (2021) Management of cancer-associated thrombosis: unmet needs and future perspectives. TH Open 5(3):e376\u2013e386. https:\/\/doi.org\/10.1055\/s-0041-1736037PMID: 34485812; PMCID: PMC8407937","journal-title":"TH Open"},{"issue":"7","key":"3154_CR39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","volume":"28","author":"TF Wang","year":"2023","unstructured":"Wang TF, Khorana AA, Agnelli G et al (2023) Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction. Oncologist 28(7):555\u2013564. https:\/\/doi.org\/10.1093\/oncolo\/oyad116PMID: 37171998; PMCID: PMC10322141","journal-title":"Oncologist"},{"key":"3154_CR40","doi-asserted-by":"crossref","unstructured":"Potere N, Mah\u00e9 I, Angchaisuksiri P, World Thrombosis Day Steering Committee and Collaborators (2024). Unmet needs and barriers in venous thromboembolism education and awareness among people living with cancer: a global survey. J Thromb Haemost 22(7):1973\u20131983. doi: 10.1016\/j.jtha.2024.03.019. Epub 2024 Apr 4. PMID: 38582384","DOI":"10.1016\/j.jtha.2024.03.019"},{"key":"3154_CR41","doi-asserted-by":"publisher","unstructured":"Kirkilesis GI, Kakkos SK, Tsolakis IA (2019) Editor\u2019s choice - A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg 57(5):685\u2013701. https:\/\/doi.org\/10.1016\/j.ejvs.2018.11.004","DOI":"10.1016\/j.ejvs.2018.11.004"},{"issue":"7","key":"3154_CR42","doi-asserted-by":"publisher","first-page":"e2325283","DOI":"10.1001\/jamanetworkopen.2023.25283","volume":"6","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Fuentes H, Deng Y et al (2023) Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis. JAMA Netw Open 6(7):e2325283. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.25283PMID: 37486628; PMCID: PMC10366701","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3154_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","volume":"6","author":"T Fujisaki","year":"2024","unstructured":"Fujisaki T, Sueta D, Yamamoto E et al (2024) Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: a systematic review and meta-analysis. JACC CardioOncol 6(1):99\u2013113. https:\/\/doi.org\/10.1016\/j.jaccao.2023.10.009PMID: 38510285; PMCID: PMC10950435","journal-title":"JACC CardioOncol"},{"issue":"9","key":"3154_CR44","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jth.14219","volume":"16","author":"AA Khorana","year":"2018","unstructured":"Khorana AA, Noble S, Lee AYY et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891\u20131894. https:\/\/doi.org\/10.1111\/jth.14219Epub 2018 Jul 19. PMID: 30027649","journal-title":"J Thromb Haemost"},{"issue":"8","key":"3154_CR45","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1111\/jth.15367","volume":"19","author":"TF Wang","year":"2021","unstructured":"Wang TF, Baumann Kreuziger L, Leader A et al (2021) Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: communication from the ISTH SSC subcommittee on hemostasis and malignancy. J Thromb Haemost 19(8):2068\u20132081. https:\/\/doi.org\/10.1111\/jth.15367","journal-title":"J Thromb Haemost"},{"key":"3154_CR46","doi-asserted-by":"crossref","unstructured":"Wang TF, Hill M, Mallick R et al (2023) The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies. Thromb Res 231:128\u2013134. doi: 10.1016\/j.thromres.2023.10.004. Epub 2023 Oct 11. PMID: 37857226","DOI":"10.1016\/j.thromres.2023.10.004"},{"issue":"4","key":"3154_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11239-023-02879-7","volume":"56","author":"B Truong","year":"2023","unstructured":"Truong B, Hornsby L, Fox BI, Chou C, Zheng J, Qian J (2023) Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: a pharmacovigilance approach. J Thromb Thrombolysis 56(4):555\u2013567. https:\/\/doi.org\/10.1007\/s11239-023-02879-7Epub 2023 Aug 10. PMID: 37563503","journal-title":"J Thromb Thrombolysis"},{"key":"3154_CR48","doi-asserted-by":"crossref","unstructured":"Kraaijpoel N, Carrier M (2019) How I treat cancer-associated venous thromboembolism. Blood 133(4):291\u2013298. doi: 10.1182\/blood-2018-08-835595. Epub 2018 Nov 26. PMID: 30478093","DOI":"10.1182\/blood-2018-08-835595"},{"key":"3154_CR49","doi-asserted-by":"publisher","unstructured":"Hakeam HA, Al-Sanea N (2017) Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). J Thromb Thrombolysis 43(3):343\u2013351. https:\/\/doi.org\/10.1007\/s11239-016-1465-x. PMID: 28050755","DOI":"10.1007\/s11239-016-1465-x"},{"key":"3154_CR50","doi-asserted-by":"publisher","first-page":"1052053","DOI":"10.3389\/fcvm.2022.1052053","volume":"9","author":"L Cappannoli","year":"2022","unstructured":"Cappannoli L, Laborante R, Galli M et al (2022) Feasibility, effectiveness, and safety of Edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study. Front Cardiovasc Med 9:1052053. https:\/\/doi.org\/10.3389\/fcvm.2022.1052053PMID: 36620634; PMCID: PMC9815104","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"3154_CR51","doi-asserted-by":"publisher","first-page":"746","DOI":"10.23736\/S0026-4806.21.07578-9","volume":"112","author":"N Potere","year":"2021","unstructured":"Potere N, Candeloro M, Porreca E, Di Nisio M (2021) Management of upper extremity deep vein thrombosis: an updated review of the literature. Minerva Med 112(6):746\u2013754. https:\/\/doi.org\/10.23736\/S0026-4806.21.07578-9Epub 2021 May 10. PMID: 33969964","journal-title":"Minerva Med"},{"issue":"4","key":"3154_CR52","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1182\/bloodadvances.2020003136","volume":"5","author":"M Yan","year":"2021","unstructured":"Yan M, Kieser R, Wu CC, Qiao W, Rojas-Hernandez CM (2021) Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients. Blood Adv 5(4):1050\u20131058. https:\/\/doi.org\/10.1182\/bloodadvances.2020003136PMID: 33599740; PMCID: PMC7903222","journal-title":"Blood Adv"},{"issue":"1","key":"3154_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.acvd.2023.11.011","volume":"117","author":"A Elias","year":"2024","unstructured":"Elias A, Debourdeau P, Espitia O, INNOVTE CAT Working Group et al (2024) Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: diagnosis and therapeutic management. Arch Cardiovasc Dis 117(1):72\u201383 Epub 2023 Nov 23. PMID: 38065755","journal-title":"Arch Cardiovasc Dis"},{"key":"3154_CR54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.thromres.2020.01.010","volume":"187","author":"J van Es","year":"2020","unstructured":"van Es J, Cheung YW, van Es N et al (2020) Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients. Thromb Res 187:125\u2013130. https:\/\/doi.org\/10.1016\/j.thromres.2020.01.010Epub 2020 Jan 20. PMID: 31986475","journal-title":"Thromb Res"},{"key":"3154_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijcard.2022.04.068","volume":"358","author":"A Tirandi","year":"2022","unstructured":"Tirandi A, Preda A, Carbone F, Montecucco F, Liberale L (2022) Pulmonary embolism in patients with cancer: an updated and operative guide for diagnosis and management. Int J Cardiol 358:95\u2013102. https:\/\/doi.org\/10.1016\/j.ijcard.2022.04.068Epub 2022 Apr 27. PMID: 35489655","journal-title":"Int J Cardiol"},{"issue":"7","key":"3154_CR56","doi-asserted-by":"publisher","first-page":"e2011079","DOI":"10.1001\/jamanetworkopen.2020.11079","volume":"3","author":"S Balabhadra","year":"2020","unstructured":"Balabhadra S, Kuban JD, Lee S et al (2020) Association of inferior Vena Cava filter placement with rates of pulmonary embolism in patients with cancer and acute lower extremity deep venous thrombosis. JAMA Netw Open 3(7):e2011079. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.11079PMID: 32701160; PMCID: PMC7378756","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3154_CR57","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","volume":"78","author":"C Hsu","year":"2021","unstructured":"Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI (2021) Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. J Am Coll Cardiol 78(6):625\u2013631 PMID: 34353538; PMCID: PMC8552338","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3154_CR58","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1182\/blood-2017-04-780148","volume":"130","author":"R Asselta","year":"2017","unstructured":"Asselta R, Paraboschi EM, Rimoldi V et al (2017) Exploring the global landscape of genetic variation in coagulation factor XI deficiency. Blood 130(4):e1\u2013e6. https:\/\/doi.org\/10.1182\/blood-2017-04-780148Epub 2017 Jun 14. PMID: 28615222","journal-title":"Blood"},{"key":"3154_CR59","doi-asserted-by":"publisher","unstructured":"Asakai R, Chung DW, Davie EW, Seligsohn U (1991) Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 325(3):153-8. https:\/\/doi.org\/10.1056\/NEJM199107183250303. PMID: 2052060","DOI":"10.1056\/NEJM199107183250303"},{"issue":"8","key":"3154_CR60","doi-asserted-by":"publisher","first-page":"e019644","DOI":"10.1161\/JAHA.120.019644","volume":"10","author":"S Yuan","year":"2021","unstructured":"Yuan S, Burgess S, Laffan M et al (2021) Genetically proxied inhibition of coagulation factors and risk of cardiovascular disease: a Mendelian randomization study. J Am Heart Assoc 10(8):e019644. https:\/\/doi.org\/10.1161\/JAHA.120.019644Epub 2021 Apr 9. PMID: 33834859; PMCID: PMC8174173","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"3154_CR61","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","volume":"50","author":"B Georgi","year":"2019","unstructured":"Georgi B, Mielke J, Chaffin M et al (2019) Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI. Stroke 50(11):3004\u20133012. https:\/\/doi.org\/10.1161\/STROKEAHA.119.026545Epub 2019 Sep 27. PMID: 31558144; PMCID: PMC6824502","journal-title":"Stroke"},{"issue":"1","key":"3154_CR62","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jth.13181","volume":"14","author":"JE Geddings","year":"2016","unstructured":"Geddings JE, Hisada Y, Boulaftali Y et al (2016) Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost 14(1):153\u2013166. https:\/\/doi.org\/10.1111\/jth.13181Epub 2015 Dec 11","journal-title":"J Thromb Haemost"},{"issue":"9","key":"3154_CR63","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/j.1538-7836.2008.02987.x","volume":"6","author":"M Davila","year":"2008","unstructured":"Davila M, Amirkhosravi A, Coll E et al (2008) Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 6(9):1517\u20131524. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.02987.xEpub 2008 Apr 22. PMID: 18433463","journal-title":"J Thromb Haemost"},{"issue":"13","key":"3154_CR64","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","volume":"123","author":"JW Yau","year":"2014","unstructured":"Yau JW, Liao P, Fredenburgh JC et al (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123(13):2102\u20132107. https:\/\/doi.org\/10.1182\/blood-2013-12-540872Epub 2014 Feb 5. PMID: 24501216","journal-title":"Blood"},{"issue":"19","key":"3154_CR65","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","volume":"116","author":"Q Cheng","year":"2010","unstructured":"Cheng Q, Tucker EI, Pine MS et al (2010) A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 116(19):3981\u20133989. https:\/\/doi.org\/10.1182\/blood-2010-02-270918Epub 2010 Jul 15. PMID: 20634381","journal-title":"Blood"},{"key":"3154_CR66","doi-asserted-by":"publisher","unstructured":"Shim YJ, Chatterjee V, Swaidani S et al (2021) Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation. Blood Adv 5(22):4741\u20134751. https:\/\/doi.org\/10.1182\/bloodadvances.2021005116. PMID: 34597365","DOI":"10.1182\/bloodadvances.2021005116"},{"key":"3154_CR67","doi-asserted-by":"publisher","unstructured":"Swystun LL, Mukherjee S, Liaw PC (2011) Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 9(11):2313-21. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04465.x. PMID: 21838758","DOI":"10.1111\/j.1538-7836.2011.04465.x"},{"issue":"1","key":"3154_CR68","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1038\/s41598-017-06893-7","volume":"7","author":"AC Leal","year":"2017","unstructured":"Leal AC, Mizurini DM, Gomes T et al (2017) Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci Rep 7(1):6438. https:\/\/doi.org\/10.1038\/s41598-017-06893-7PMID: 28743887; PMCID: PMC5526939","journal-title":"Sci Rep"},{"key":"3154_CR69","doi-asserted-by":"publisher","unstructured":"Occhipinti G, Laudani C, Spagnolo M et al (2024) Pharmacological and clinical appraisal of factor XI inhibitor drugs. Eur Heart J Cardiovasc Pharmacother 10(3):245\u2013258. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae002. PMID: 38196141","DOI":"10.1093\/ehjcvp\/pvae002"},{"key":"3154_CR70","doi-asserted-by":"publisher","unstructured":"Johnson CY, Tuite A, Morange PE, Tregouet DA, Gagnon F (2011) The factor XII\u2013\u20094C\u2009>\u2009T variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. Am J Epidemiol 173(2):136\u201344. https:\/\/doi.org\/10.1093\/aje\/kwq349. Epub 2010 Nov 11. PMID: 21071604","DOI":"10.1093\/aje\/kwq349"},{"issue":"13","key":"3154_CR71","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","volume":"108","author":"CJ Doggen","year":"2006","unstructured":"Doggen CJ, Rosendaal FR, Meijers JC (2006) Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 108(13):4045\u20134051. https:\/\/doi.org\/10.1182\/blood-2005-12-023697Epub 2006 Aug 24. PMID: 16931632","journal-title":"Blood"},{"issue":"11","key":"3154_CR72","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M et al (2023) Pharmacology and clinical development of factor XI inhibitors. Circulation 147(11):897\u2013913. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062353Epub 2023 Mar 13. PMID: 36913497","journal-title":"Circulation"},{"issue":"2","key":"3154_CR73","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jth.15577","volume":"20","author":"BA Yi","year":"2022","unstructured":"Yi BA, Freedholm D, Widener N et al (2022) Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa. J Thromb Haemost 20(2):307\u2013315. https:\/\/doi.org\/10.1111\/jth.15577Epub 2021 Nov 19. PMID: 34714969","journal-title":"J Thromb Haemost"},{"issue":"13","key":"3154_CR74","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","volume":"133","author":"AW Koch","year":"2019","unstructured":"Koch AW, Schiering N, Melkko S et al (2019) MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood 133(13):1507\u20131516. https:\/\/doi.org\/10.1182\/blood-2018-10-880849Epub 2019 Jan 28. PMID: 30692123","journal-title":"Blood"},{"key":"3154_CR75","doi-asserted-by":"publisher","unstructured":"van Es N, De Caterina R, Weitz JI (2023) Reversal agents for current and forthcoming direct oral anticoagulants. Eur Heart J 44(20):1795\u20131806. https:\/\/doi.org\/10.1093\/eurheartj\/ehad123. PMID: 36988142","DOI":"10.1093\/eurheartj\/ehad123"},{"issue":"1","key":"3154_CR76","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","volume":"44","author":"MA Pfeffer","year":"2024","unstructured":"Pfeffer MA, Kohs TCL, Vu HH et al (2024) Factor XI inhibition for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement: a phase 2 clinical trial. Arterioscler Thromb Vasc Biol 44(1):290\u2013299. https:\/\/doi.org\/10.1161\/ATVBAHA.123.319692Epub 2023 Nov 16. PMID: 37970718; PMCID: PMC10877270","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3154_CR77","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","volume":"39","author":"CU Lorentz","year":"2019","unstructured":"Lorentz CU, Verbout NG, Wallisch M et al (2019) Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial. Arterioscler Thromb Vasc Biol 39:799\u2013809","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"3154_CR78","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40265-024-02049-w","volume":"84","author":"M Galli","year":"2024","unstructured":"Galli M, Occhipinti G, Ortega-Paz L et al (2024) Therapeutic potential of FXI inhibitors: hype or hope?? Drugs 84(9):1055\u20131070. https:\/\/doi.org\/10.1007\/s40265-024-02049-wEpub 2024 Jul 29. PMID: 39073551","journal-title":"Drugs"},{"key":"3154_CR79","doi-asserted-by":"publisher","unstructured":"Singh S, Kumar P, Yadav SK et al (2025) Recent pathophysiological insights are advancing the treatment of venous thromboembolism. JACC: basic to translational science. Published Online Febr 26. https:\/\/doi.org\/10.1016\/j.jacbts.2024.12.004","DOI":"10.1016\/j.jacbts.2024.12.004"},{"issue":"5","key":"3154_CR80","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1055\/a-1653-4699","volume":"122","author":"O Sanchez","year":"2022","unstructured":"Sanchez O, Charles-Nelson A, Ageno W et al (2022) PEITHO-3 investigators. Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: rationale and design of the pulmonary embolism international thrombolysis (PEITHO)-3 trial. Thromb Haemost 122(5):857\u2013866. https:\/\/doi.org\/10.1055\/a-1653-4699Epub 2021 Oct 31. PMID: 34560806; PMCID: PMC9197594","journal-title":"Thromb Haemost"},{"key":"3154_CR81","doi-asserted-by":"publisher","first-page":"622473","DOI":"10.3389\/fcvm.2020.622473","volume":"7","author":"M Sillen","year":"2020","unstructured":"Sillen M, Declerck PJ (2020) Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition. Front Cardiovasc Med 7:622473. https:\/\/doi.org\/10.3389\/fcvm.2020.622473PMID: 33415130; PMCID: PMC7782431","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"3154_CR82","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/ijms22020883","volume":"22","author":"K Claesen","year":"2021","unstructured":"Claesen K, Mertens JC, Leenaerts D, Hendriks D, Carboxypeptidase (2021) U (CPU, tafia, CPB2) in thromboembolic disease: what do we know three decades after its discovery?? Int J Mol Sci 22(2):883. https:\/\/doi.org\/10.3390\/ijms22020883PMID: 33477318; PMCID: PMC7830380","journal-title":"Int J Mol Sci"},{"key":"3154_CR83","doi-asserted-by":"publisher","unstructured":"Mackman N, Bergmeier W, Stouffer GA, Weitz JI (2020) Therapeutic strategies for thrombosis: new targets and approaches. Nat Rev Drug Discov 19(5):333\u2013352. https:\/\/doi.org\/10.1038\/s41573-020-0061-0. Epub 2020 Mar 4. PMID: 32132678","DOI":"10.1038\/s41573-020-0061-0"},{"key":"3154_CR84","doi-asserted-by":"publisher","unstructured":"Khera R, Asnani AH, Krive J, American Heart Association Cardio-Oncology and Data Science and Precision Medicine Committees of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; Council on Cardiovascular Radiology and Intervention; and Council on Cardiovascular and Stroke Nursing (2025). Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: a Scientific Statement From the American Heart Association. Circ Genom Precis Med. Feb 24:e000097. https:\/\/doi.org\/10.1161\/HCG.0000000000000097. PMID: 39989357","DOI":"10.1161\/HCG.0000000000000097"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03154-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03154-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03154-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:38:30Z","timestamp":1781613510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03154-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":84,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3154"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03154-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"10 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}